Infertility now affects one in six couples worldwide, yet the tools available to treat male infertility have hardly changed in half a century. For millions of families hoping for children, the standard options—hormonal therapies, surgery, or IVF—remain unpredictable at best and ineffective at worst. Half of all IVF failures stem from male factors, leaving couples with few answers and fewer alternatives.

Paterna Biosciences is rewriting that story. Founded by physicians and scientists who have spent more than a decade delivering the heartbreaking news that nothing more could be done, the company is pioneering a radically different approach: creating functional sperm entirely outside the human body. By guiding spermatogonial stem cells through in vitro spermatogenesis, Paterna aims to give men with previously untreatable infertility a true chance at biological parenthood.

This breakthrough could alter not only how fertility treatment works, but how we think about reproduction itself. For the first time, the male side of the equation—long overlooked and underfunded—is at the center of innovation. And as Paterna advances toward clinical readiness, it’s offering something the fertility community has never had before: a path forward where certainty replaces luck, and hope finally has science behind it.

OpenLoop is redefining how modern telehealth is delivered. By providing the plug-and-play infrastructure, clinician network, and operational backbone behind today’s fastest-growing virtual care companies, OpenLoop enables any organization to launch compliant, scalable care delivery in all 50 states. What started in rural Iowa is now powering more than a million patient visits—and bringing healthcare closer to the people who need it most.

Chronic disease management in America is broken—not because technology doesn’t exist, but because too often it forgets the people it’s meant to serve. With over 133 million Americans living with chronic conditions and average primary care waits topping 30 days, patients are left in limbo. Tenovi is changing that with a simpler, plug-and-play approach to remote care. No apps. No Wi-Fi. Just devices that work straight out of the box, connecting patients to their care teams instantly. It’s a quiet revolution in digital health—one built on accessibility, equity, and the radical idea that technology should make care easier, not harder.

Obesity is one of the most pressing health challenges of our time—but too often, patients are met with stigma instead of support. FlyteHealth is changing that. By combining cutting-edge clinical intelligence with deeply personalized care, the company is redefining how we treat obesity—not as a character flaw, but as a complex, chronic condition that deserves expert, compassionate intervention.

Tava Health, a trailblazing mental health company, successfully completed a $20 million Series B funding round led by Catalyst Investors.

We are pleased to share that Dan Lambert, CEO and co-founder of our portfolio company  PathologyWatch, was named one of the Top 35 Digital Health Leaders by  Slice of Healthcare. 

Vytalize Health earned the top spot on the Inc. 5000 list by achieving extraordinary growth—over 90,000% in three years.

It’s no understatement to say that Sloan Saunders constantly has the weight of the world on his mind.

Nest Health, a startup providing in-home and virtual care to families, picked up over $4 million in an extended seed round to expand to new markets and fuel partnerships with health plans.

We are thrilled to announce that our portfolio company, OpenLoop, has received the LegitScript Healthcare Merchant Certification.

OpenLoop, a leader in white-label telehealth support services powering virtual care across the country, today announced a partnership with BlueJeans by Verizon to propel anytime, anywhere virtual care delivery.

We are excited to announce that our portfolio company OpenLoop, a leading white-label telehealth support company has raised a $15M Series A funding.

Salt Lake City-based Pathology Watch has announced it has been acquired by Sonic Healthcare, headquartered in Sydney, Australia, for $150 million.

We are pleased to share that Scott Mattivi, COO of our portfolio company PathologyWatch, earned the Meritorious Achievement Award from Pittsburg State University.

Clinicians don’t need to take a blood, sweat, and tears sample to arrive at the diagnosis that clinician burnout is at an all-time high and health systems are struggling to provide the support and tools needed amid large financial losses.